Nimra (Tranexamic Acid)

Tranexamic acid blocks the conversion of plasminogen to plasmin by binding to lysine‑binding sites on the plasminogen molecule. This inhibition prevents fibrin degradation, thereby preserving clot integrity and limiting excessive bleeding. The action is localized to the site of hemorrhage and does not directly affect platelet function or the coagulation cascade.

The dosage of Nimra is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and overall clinical assessment. Healthcare professionals determine the appropriate strength, frequency, and duration of therapy in accordance with established treatment guidelines and the patient’s medical history.

Safety data for tranexamic acid in pregnancy and lactation are limited, and the drug should only be used when the potential benefit outweighs any possible risk to the fetus or infant. Prescribers typically evaluate maternal health, bleeding severity, and alternative options before deciding on therapy during pregnancy or while nursing.

To request Nimra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Nimra’s active ingredient, tranexamic acid, is a widely used antifibrinolytic that offers oral administration and a well‑characterized safety profile. Compared with alternatives such as aminocaproic acid, tranexamic acid generally provides stronger inhibition of fibrinolysis, requires lower doses, and has a more predictable pharmacokinetic profile, making it a preferred choice in many surgical and obstetric settings.

Nimra should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use. Do not refrigerate or freeze the tablets, as temperature extremes may affect stability.

Nimra is supplied as an oral formulation that is taken by mouth with or without water, as directed by the prescribing clinician. The exact timing—such as before a surgical procedure or during a menstrual cycle—depends on the indication and the dosage schedule determined by the healthcare provider.

The most serious concerns involve the potential for thromboembolic events, such as deep‑vein thrombosis or pulmonary embolism, especially in patients with pre‑existing clotting disorders. Rare but severe reactions can include visual disturbances, severe allergic responses, and sudden hypotension when administered rapidly intravenously. Prompt medical attention is required if these symptoms arise.

Nimra is contraindicated in individuals with active intravascular clot formation, a known hypersensitivity to tranexamic acid, or those who have experienced previous thrombotic complications without adequate anticoagulation. Patients with severe renal impairment may also require alternative therapy, and the decision should be made by a qualified healthcare professional.